Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,521 across all filing types
Latest filing 2022-10-28 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
DIVERSITY OF BOARD MEMBERS - NON-COMPLIANCE WITH RULE 13.92 OF THE LISTING RULES
Board/Management Information Classification · 95% confidence The document is an announcement regarding non-compliance with a board diversity rule (Rule 13.92 of the Listing Rules) due to the resignation of a female independent non-executive director, resulting in a single gender board. It discusses the board composition and plans to appoint a suitable female candidate to comply with the listing rules. There is no financial data, no report attached or referenced as published, and no mention of a meeting or voting results. The content focuses on board composition and compliance with governance rules. This fits the category of Board/Management Information (MANG), which covers announcements of changes or issues related to the company's board of directors or senior management.
2022-10-28 English
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE "SYS6002" OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new antibody-drug conjugate product. It is an announcement of a regulatory milestone related to the company's product development, not a financial report, management change, or shareholder meeting material. The document is short (2245 characters) and does not contain financial data, earnings, or detailed management discussion. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category about company developments. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-10-27 English
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THIRD QUARTER OF 2022
Interim / Quarterly Report Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the principal financial information of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. for the third quarter of 2022. It references the third quarter report published by the subsidiary on the Shenzhen Stock Exchange website and provides detailed financial data such as revenue, net profit, cash flows, and changes in accounting data. The document is lengthy (over 12,000 characters) and contains substantive financial data and analysis for a period shorter than a full fiscal year (the third quarter). It is not merely an announcement of a report publication but includes actual financial statements and explanations. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-10-24 English
VOLUNTARY ANNOUNCEMENT - "TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the drug registration approval of a pharmaceutical product. It is a short announcement (2543 characters) that informs about a regulatory approval event and does not contain financial data, financial statements, or detailed management discussion. It is not a report, transcript, or detailed presentation. The document is an announcement of a corporate event related to product approval, which fits best under the category of Regulatory Filings (RNS) as it does not fit into any other more specific category such as financial reports, management changes, or capital updates.
2022-10-24 English
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH HARBOUR BIOMED (SHANGHAI) CO., LTD. FOR BATOCLIMAB (HBM9161)
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding an exclusive license agreement with Harbour Biomed (Shanghai) Co., Ltd. It details the terms of the agreement, including payments and royalties, and provides background information on the licensed product and the involved companies. The document is relatively short (3747 characters) and does not contain financial statements, regulatory filings, or detailed financial performance data. It is an announcement of a business transaction (license agreement) rather than a full report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including licensing agreements that involve significant payments and milestones.
2022-10-10 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2022
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 September 2022. It details movements in issued shares, share options, and confirms no changes in authorized share capital or other agreements. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movements for a specific month. It does not contain financial statements, earnings data, or management discussion. It is a regulatory filing related to share capital movements and compliance with listing rules, not a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS). The document length is about 5106 characters, which is sufficient for a detailed regulatory filing rather than a brief announcement.
2022-10-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.